SCHEMBL719502

SCHEMBL719502

CCC(O)c1oc2ccc(OCc3ccccc3)cc2c1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.56
PKM P14618 1/20 0.56
CASP3 P42574 2/20 0.56
SENP8 Q96LD8 2/20 0.56
SENP7 Q9BQF6 2/20 0.56
SENP6 Q9GZR1 2/20 0.56
MAOB P27338 5/20 0.51
ACHE P22303 1/20 0.51
MAOA P21397 4/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
SLC26A4 O43511 3/20 0.46
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
BLM P54132 1/20 0.46
ATM Q13315 1/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL721773 0.88 L3MBTL1 (0.54) L3MBTL1PKMCASP3SENP8SENP7
SCHEMBL718464 0.88 L3MBTL1 (0.58) L3MBTL1PKMCASP3SENP8SENP7
SCHEMBL717029 0.85 L3MBTL1 (0.56) L3MBTL1PKMCASP3SENP8SENP7
SCHEMBL718421 0.82 L3MBTL1 (0.50) L3MBTL1PKMCASP3SENP8SENP7
SCHEMBL719690 0.79 L3MBTL1 (0.60) L3MBTL1PKMCASP3SENP8SENP7
SCHEMBL717397 0.77 CASP3 (0.61) L3MBTL1PKMCASP3SENP8SENP7
SCHEMBL3399151 0.77 L3MBTL1 (0.57) L3MBTL1PKMCASP3SENP8SENP7
SCHEMBL720239 0.77 CASP3 (0.70) L3MBTL1PKMCASP3SENP8SENP7
SCHEMBL717067 0.76 KDM4E (0.62) L3MBTL1PKMCASP3SENP8SENP7
SCHEMBL720265 0.76 CASP3 (0.60) L3MBTL1PKMCASP3SENP8SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP L3MBTL1 4088/4885PKM 2662/4885CASP3 489/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP L3MBTL1 4088/4885PKM 2662/4885CASP3 489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.